Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects

Overview

Journal Clin Pharmacol Drug Dev

Publisher Wiley

Specialty Pharmacology

Date 2016 Sep 23

PMID 27652589

Citations 1

Authors

Kazuo Umemura

Yasuhiko Ikeda

Nobuko Matsushima

Kazunao Kondo

Affiliations

Soon will be listed here.

Abstract

We evaluated the pharmacokinetics and pharmacodynamics of prasugrel used in combination with aspirin in healthy Japanese subjects. All subjects received aspirin 100 mg/day. Subsequently, in the single-administration study, 23 subjects also received prasugrel 20 or 30 mg, and in the multiple-administration study, 20 subjects received a loading dose of prasugrel 20 or 30 mg on day 1, followed by a maintenance dose of prasugrel 5 or 7.5 mg/day, respectively, on days 2-5. In both studies, the plasma concentration of the active metabolite of prasugrel, R-138727, reached a maximum 0.5 hours after administration and rapidly decreased within 4 hours. In the single-administration study, the inhibitory effect on adenosine diphosphate-induced platelet aggregation was significantly higher in the prasugrel 20- and 30-mg groups than in the placebo group at all times (1-144 hours) after administration. In the multiple-administration study, a similar antiplatelet effect was found after both the loading dose and the maintenance dose and was maintained for 3-6 days after the last administration. There were study drug-related adverse events; however, all were mild, and none was clinically significant.

Citing Articles

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.

Li X, Liu C, Zhu X, Wei H, Zhang H, Chen H Front Pharmacol. 2018; 9:643.

PMID: 29973877 PMC: 6019484. DOI: 10.3389/fphar.2018.00643.

References

Riesmeyer J, Salazar D, Weerakkody G, Ni L, Wrishko R, Ernest 2nd C . Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol. 2011; 52(6):789-97. DOI: 10.1177/0091270011406280. View

Small D, Kothare P, Yuen E, Lachno D, Li Y, Winters K . The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol. 2009; 66(2):127-35. DOI: 10.1007/s00228-009-0737-1. View

Jakubowski J, Payne C, Li Y, Farid N, Brandt J, Small D . A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost. 2008; 99(1):215-22. DOI: 10.1160/TH07-09-0555. View

Small D, Li Y, Ernest 2nd C, April J, Farid N, Payne C . Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol. 2010; 51(3):321-32. DOI: 10.1177/0091270010367429. View

Brandt J, Payne C, Wiviott S, Weerakkody G, Farid N, Small D . A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2006; 153(1):66.e9-16. DOI: 10.1016/j.ahj.2006.10.010. View

Kushner F, Hand M, Smith Jr S, King 3rd S, Anderson J, Antman E . 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the.... J Am Coll Cardiol. 2009; 54(23):2205-41. DOI: 10.1016/j.jacc.2009.10.015. View

Umemura K, Ikeda Y, Kondo K . Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects. Drug Metab Pharmacokinet. 2016; 31(4):285-91. DOI: 10.1016/j.dmpk.2016.03.006. View

Jakubowski J, Payne C, Weerakkody G, Brandt J, Farid N, Li Y . Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007; 49(3):167-73. DOI: 10.1097/FJC.0b013e318031301b. View

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro P, Saut N . Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol. 2013; 111(7):985-90. DOI: 10.1016/j.amjcard.2012.12.013. View

10.

Niitsu Y, Jakubowski J, Sugidachi A, Asai F . Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005; 31(2):184-94. DOI: 10.1055/s-2005-869524. View

11.

Steg P, James S, Atar D, Badano L, Blomstrom-Lundqvist C, Borger M . ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20):2569-619. DOI: 10.1093/eurheartj/ehs215. View

12.

Umemura K, Iwaki T . The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers. Clin Pharmacol Drug Dev. 2016; 5(6):480-487. PMC: 5132138. DOI: 10.1002/cpdd.259. View

13.

Rehmel J, Eckstein J, Farid N, Heim J, Kasper S, Kurihara A . Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006; 34(4):600-7. DOI: 10.1124/dmd.105.007989. View

14.

Ernest 2nd C, Small D, Rohatagi S, Salazar D, Wallentin L, Winters K . Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008; 35(6):593-618. DOI: 10.1007/s10928-008-9103-7. View

15.

Kuster L, Frolich J . Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins. 1986; 32(3):415-23. DOI: 10.1016/0090-6980(86)90009-2. View

16.

Small D, Payne C, Kothare P, Yuen E, Natanegara F, Loh M . Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther. 2010; 32(2):365-79. DOI: 10.1016/j.clinthera.2010.02.015. View

17.

Farid N, Payne C, Small D, Winters K, Ernest 2nd C, Brandt J . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; 81(5):735-41. DOI: 10.1038/sj.clpt.6100139. View

18.

Erlinge D, Berg J, Foley D, Angiolillo D, Wagner H, Brown P . Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012; 60(20):2032-40. DOI: 10.1016/j.jacc.2012.08.964. View

19.

Ballem P, Belzberg A, Devine D, Lyster D, Spruston B, Chambers H . Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992; 327(25):1779-84. DOI: 10.1056/NEJM199212173272503. View

20.

Brandt J, Close S, Iturria S, Payne C, Farid N, Ernest 2nd C . Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007; 5(12):2429-36. DOI: 10.1111/j.1538-7836.2007.02775.x. View